Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas

Research output: Contribution to journalReview article

Abstract

Soft tissue sarcomas (STS) represent a variety of tumors of mesenchymal origin, accounting for about 1% of all adult cancers. This group of tumors comprises over 60 different histotypes with different biology showing different sensitivity to therapeutic agents. For decades, the standard first-line systemic treatment of metastatic STS has comprised anthracycline based-chemotherapy. Second-line therapy options include agents such as ifosfamide, gemcitabine, and pazopanib, but the optimal sequential therapy for the management of metastatic disease has yet to be defined. Trabectedin is one of the new molecules approved for patients in progression after first-line chemotherapy with anthracyclines or for those unfit for these agents. The compound is characterized by multiple potential mechanisms of action combining cytotoxic, targeted, and immunological effects. This article takes an in-depth look at the role of trabectedin in the management of metastatic STS, including L-sarcoma and non-L-sarcoma.

Original languageEnglish
Pages (from-to)1155-1164
Number of pages10
JournalOncoTargets and Therapy
Volume10
DOIs
Publication statusPublished - 2017

Fingerprint

trabectedin
Sarcoma
Anthracyclines
gemcitabine
Therapeutics
Drug Therapy
Neoplasms
Ifosfamide
Disease Management
Action Potentials

Keywords

  • Journal Article
  • Review

Cite this

@article{0795413a408740198d843f80f9d2cad4,
title = "Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas",
abstract = "Soft tissue sarcomas (STS) represent a variety of tumors of mesenchymal origin, accounting for about 1{\%} of all adult cancers. This group of tumors comprises over 60 different histotypes with different biology showing different sensitivity to therapeutic agents. For decades, the standard first-line systemic treatment of metastatic STS has comprised anthracycline based-chemotherapy. Second-line therapy options include agents such as ifosfamide, gemcitabine, and pazopanib, but the optimal sequential therapy for the management of metastatic disease has yet to be defined. Trabectedin is one of the new molecules approved for patients in progression after first-line chemotherapy with anthracyclines or for those unfit for these agents. The compound is characterized by multiple potential mechanisms of action combining cytotoxic, targeted, and immunological effects. This article takes an in-depth look at the role of trabectedin in the management of metastatic STS, including L-sarcoma and non-L-sarcoma.",
keywords = "Journal Article, Review",
author = "Federica Recine and Alberto Bongiovanni and Nada Riva and Valentina Fausti and {De Vita}, Alessandro and Laura Mercatali and Chiara Liverani and Giacomo Miserocchi and Dino Amadori and Toni Ibrahim",
year = "2017",
doi = "10.2147/OTT.S127955",
language = "English",
volume = "10",
pages = "1155--1164",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas

AU - Recine, Federica

AU - Bongiovanni, Alberto

AU - Riva, Nada

AU - Fausti, Valentina

AU - De Vita, Alessandro

AU - Mercatali, Laura

AU - Liverani, Chiara

AU - Miserocchi, Giacomo

AU - Amadori, Dino

AU - Ibrahim, Toni

PY - 2017

Y1 - 2017

N2 - Soft tissue sarcomas (STS) represent a variety of tumors of mesenchymal origin, accounting for about 1% of all adult cancers. This group of tumors comprises over 60 different histotypes with different biology showing different sensitivity to therapeutic agents. For decades, the standard first-line systemic treatment of metastatic STS has comprised anthracycline based-chemotherapy. Second-line therapy options include agents such as ifosfamide, gemcitabine, and pazopanib, but the optimal sequential therapy for the management of metastatic disease has yet to be defined. Trabectedin is one of the new molecules approved for patients in progression after first-line chemotherapy with anthracyclines or for those unfit for these agents. The compound is characterized by multiple potential mechanisms of action combining cytotoxic, targeted, and immunological effects. This article takes an in-depth look at the role of trabectedin in the management of metastatic STS, including L-sarcoma and non-L-sarcoma.

AB - Soft tissue sarcomas (STS) represent a variety of tumors of mesenchymal origin, accounting for about 1% of all adult cancers. This group of tumors comprises over 60 different histotypes with different biology showing different sensitivity to therapeutic agents. For decades, the standard first-line systemic treatment of metastatic STS has comprised anthracycline based-chemotherapy. Second-line therapy options include agents such as ifosfamide, gemcitabine, and pazopanib, but the optimal sequential therapy for the management of metastatic disease has yet to be defined. Trabectedin is one of the new molecules approved for patients in progression after first-line chemotherapy with anthracyclines or for those unfit for these agents. The compound is characterized by multiple potential mechanisms of action combining cytotoxic, targeted, and immunological effects. This article takes an in-depth look at the role of trabectedin in the management of metastatic STS, including L-sarcoma and non-L-sarcoma.

KW - Journal Article

KW - Review

U2 - 10.2147/OTT.S127955

DO - 10.2147/OTT.S127955

M3 - Review article

C2 - 28260930

VL - 10

SP - 1155

EP - 1164

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -